FDA Clinical Investigator Training Course (CITC) 2024 - Day Two - Session One
Рет қаралды 566
Күн бұрынThis annual training course provided participants with the essential knowledge and skills to conduct clinical trials effectively, ethically, and in accordance with regulatory standards. Session one of day two covered topics such as Chemistry, Manufacturing, and Controls (CMC) and Why Clinical Pharmacology is Essential in Drug Development.
01:42 - Chemistry, Manufacturing and Controls: Regulatory Considerations Through Clinical Development
31:17 - Pharmacology & Toxicology in the Investigator's Brochure
59:30 - Clinical Pharmacology: Early Drug Development
01:22:20 - Q&A Discussion Panel
Speakers | Panelists
Paresma Patel, PhD
Director
Division of Product Quality Assessment XIX (DPQAXIX)
Office of Product Quality Assessment (OPQA)
III Office of Pharmaceutical Quality (OPQ)
CDER | FDA
Nikolett Biel, PhD
Senior Biologist
Division of Hematology Oncology Toxicology (DHOT)
Office of Oncologic Diseases (OOD) Office of New Drugs (OND) | CDER | FDA
Shirley K. Seo, PhD
Director
Division of Cardiometabolic and Endocrine Pharmacology (DCEP)
Office of Clinical Pharmacology (OCP)
Office of Translational Sciences (OTS)
CDER | FDA
(Moderator)
Leonard Sacks, MBBCh
Associate Director for Clinical Methodologies
Office of Medical Policy (OMP)
CDER | FDA
Learn more at: www.fda.gov/dr...
-----------------------
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming Training - www.fda.gov/cd...
SBIA Listserv - public.govdeli...
SBIA 2024 Playlist - • 2024 CDER Small Busine...
SBIA LinkedIn - / cder-small-business-an...
SBIA Training Resources - www.fda.gov/cd...
Twitter - / fda_drug_info
Email - CDERSBIA@fda.hhs.gov
Phone - (301) 796-6707 I (866) 405-5367
U.S. Food and Drug Administration
Рет қаралды 516
U.S. Food and Drug Administration
Рет қаралды 714
Nikita Zdradovskiy
Рет қаралды 7 МЛН
That Little Puff
Рет қаралды 24 МЛН
U.S. Food and Drug Administration
Рет қаралды 355
U.S. Food and Drug Administration
Рет қаралды 834
U.S. Food and Drug Administration
Рет қаралды 1,5 М.
U.S. Food and Drug Administration
Рет қаралды 1,6 М.
U.S. Food and Drug Administration
Рет қаралды 214
U.S. Food and Drug Administration
Рет қаралды 237
U.S. Food and Drug Administration
Рет қаралды 578
FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory...
U.S. Food and Drug Administration
Рет қаралды 414
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic aci...
U.S. Food and Drug Administration
Рет қаралды 319
Nikita Zdradovskiy
Рет қаралды 7 МЛН